ReviewAlzheimer's research & therapy2022
Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease.
Review in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Risk factors of mild behavioral impairment: a systematic review.Frontiers in psychology · 2025Pooled it
- Cross-sectional associations of loneliness with plasma p-tau217 and neurofilament light chain in dementia-free older adults in the INSPIRE-T baseline cohort.Journal of Alzheimer's disease : JAD · 2026Article
- Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Rostral associations of MRI atrophy of the amygdala and entorhinal cortex across the AD spectrum.Neuroimage. Reports · 2026Article
- Early identification of vascular cognitive impairment from a multimodal perspective: a combined diagnosis from targeted cognitive assessments, imaging biomarkers, and molecular fluid biomarkers to ecological behavioral characteristics.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Neuropsychiatric symptoms and dementia development: a 15-year population-based study.The journal of prevention of Alzheimer's disease · 2026Article
- Plasma neurofilament light chain and regional brain atrophy mediate the association of neuropsychiatric symptoms with cognition in Alzheimer's disease: evidence from two population-based studies.Psychological medicine · 2026Article
- Article
- Apathy in Mild Behavioural Impairment: Associations with Cortical Thickness and Grey Matter Volume.medRxiv : the preprint server for health sciences · 2026Article
- Characterization of neuropsychiatric symptoms in patients with early-stage Alzheimer's disease in a specialized outpatient clinic.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Observational
- Aberrant Medial Prefrontal Cortex Activity and Flexible Behavior in the TgF344-AD Rat Model of Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Functional network phenotypes of mild behavioural impairment: cognitive effects moderated by amyloid.Alzheimer's research & therapy · 2026Article
- Rostral Associations of MRI Atrophy of the Amygdala and Entorhinal Cortex Across the AD Spectrum.medRxiv : the preprint server for health sciences · 2026Article
- Validation of the Positive and Negative Affect Schedule (PANAS) in older Argentine adults.Dementia & neuropsychologia · 2026Article
- Integrated approaches to geriatric mental disorders: pathophysiology, interventions, and precision medicine horizons.Frontiers in psychiatry · 2026Review
- Mild Behavioral Impairment: A Population-Based Study.The Journal of neuropsychiatry and clinical neurosciences · 2026Article
- Depression severity and neuropsychiatric symptoms among nursing home residents with late-life depression: a moderated mediation model of sleep quality and resilience.BMC psychiatry · 2025Article
- Validity and reliability of the Italian version of the Mild Behavioral Impairment Checklist in cognitively unimpaired and mild cognitive impairment individuals.Journal of Alzheimer's disease : JAD · 2025Article
- Correlates of mild behavioural impairment in older adults: a scoping review.BMC geriatrics · 2025Article
- Neuropsychiatric symptoms and progression to pathologically confirmed Alzheimer's disease.Brain : a journal of neurology · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundLate-life onset neuropsychiatric symptoms are established risk factors for dementia. The mild behavioral impairment (MBI) diagnostic framework was designed to standardize assessment to determine dementia risk better. In this Mini Review, we summarize the emerging clinical and biomarker evidence, which suggests that for some, MBI is a marker of preclinical Alzheimer's disease. MAIN: MBI is generally more common in those with greater cognitive impairment. In community and clinical samples, frequency is around 10-15%. Mounting evidence in cognitively normal samples links MBI symptoms with known AD biomarkers for amyloid, tau, and neurodegeneration, as well as AD risk genes. Clinical studies have found detectable differences in cognition associated with MBI in cognitively unimpaired people.
conclusionThe emerging evidence from biomarker and clinical studies suggests MBI can be an early manifestation of underlying neurodegenerative disease. Future research must now further validate MBI to improve identification of those at the very earliest stages of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.